Eli Lilly releases generic insulin injection
Eli Lilly has released a generic insulin injection at half of the list price of its identical branded medicine to the US market.
City of Baltimore accuses Janssen of delaying generics
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is being sued for “unlawfully” delaying generic competition to Zytiga, its branded cancer medication.
Merck boosts oncology pipeline with $1bn deal
Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.
Alphabet's Verily in digital research alliance with Pfizer and others
Verily, which is a subsidiary of Google’s parent company Alphabet, yesterday announced that it had partnered with Novartis, Otsuka, Pfizer, and Sanofi in efforts to develop digitally-innovative clinical research programmes.
Genentech enters agreement to develop autoimmune therapies
US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.
Gilead claims US government PrEP patents are invalid
Gilead’s CEO has told a US House of Representatives committee that three Centers for Disease Control HIV prevention patents are invalid.
Delhi High Court issues landmark nutraceuticals judgment
The High Court of Delhi has ruled that the test for passing off of so-called nutraceuticals should be the same as that for pharmaceuticals.
Federal Circuit invalidates Nuvo’s Vimovo patents
The US Court of Appeals for the Federal Circuit has delivered a blow to Nuvo Pharmaceuticals by reversing a decision which had upheld the validity of the Canadian company’s pain relief drug Vimovo.
EU adopts SPC manufacturing waiver
The European Union has adopted the proposed supplementary protection certificate manufacturing waiver, despite criticism from parts of the pharmaceutical industry.
Federal Circuit rules against J&J in Zytiga dispute
The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.
